Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Has Average Target Price of $38.50

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $38.50.

A number of brokerages have recently issued reports on ALGS. HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research report on Friday, September 25th. Finally, Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th.

Aligos Therapeutics Trading Down 5.1%

Shares of ALGS stock opened at $5.23 on Monday. Aligos Therapeutics has a 52-week low of $3.98 and a 52-week high of $13.69. The business’s fifty day moving average is $5.97 and its 200 day moving average is $5.97.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.95. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. The business had revenue of $27.78 million during the quarter, compared to analysts’ expectations of $24.68 million. As a group, equities research analysts predict that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its position in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after buying an additional 216,646 shares in the last quarter. SummitTX Capital L.P. lifted its holdings in shares of Aligos Therapeutics by 6.7% during the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after acquiring an additional 9,375 shares during the last quarter. Renaissance Technologies LLC grew its position in Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after acquiring an additional 15,006 shares in the last quarter. Finally, Rockefeller Capital Management L.P. grew its position in Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis.

Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology.